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Abstract Numerous photoa⁄nity studies of the NK-1 receptor
have been carried out with peptide agonist analogues of sub-
stance P (SP). However, no information is available with regard
to the domain interaction of peptide antagonists within this
receptor. We describe herein the photoa⁄nity labelling of the
SP receptor with a peptide antagonist analogue, Bapa0[(pBzl)-
Phe8,DPro9,MePhe10,Trp(CHO)11]SP. Photolabelling, enzy-
matic or chemical cleavage of the covalent complex, puri¢cation
via streptavidin-coated beads and matrix-assisted laser desorp-
tion/ionization time of £ight mass spectrometry analysis led us
to show that the methyl of Met174 side chain, within the re-
ceptor’s second extracellular loop, is covalently linked to the
antagonist photoreactive at position 8.
8 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Most photolabelling studies on receptors have been carried
out with peptide agonists while the use of photoreactive an-
tagonists is more rare [1]. Among receptors of the rhodopsin
class I G protein-coupled receptor family, the substance P
(SP) NK-1 receptor has been widely studied with photoreac-
tive peptide agonists [2^8] whereas only one study describes
photoa⁄nity labelling with the use of a non-peptide antago-
nist, derived from CP-96,345, of the quinuclidin family [9].
Many peptide antagonists have been reported for the NK-1
receptor (see [10] for review). Generally these SP analogues
contain at least one D-Trp or a L turn type IIP constraint such
as a spirolactame, a DPro-(NMe) amino acid or DPro-alkyl-
Pro, or are modi¢ed on the C-terminal methionine [10].
To understand the molecular basis of the interaction be-
tween antagonist or agonist ligands and the NK-1 receptor,
numerous mutagenesis studies have been carried out (see [11]
for review). Until now, site-directed mutagenesis studies and
construction of deleted or chimeric NK-1 receptors led to the
conclusion that the region of the binding site for non-peptide
antagonists di¡ers from the binding site for the peptide ago-
nists [11].
Brie£y, residues of crucial importance for peptide agonist
binding were initially identi¢ed in the N-terminal extension
and in the ¢rst and second extracellular loops [11]. Substitu-
tions of these residues led to dramatic impairment in SP bind-
ing without a¡ecting non-peptide antagonist binding. In con-
trast, residues involved in the binding of antagonists lie in
bundles between transmembrane domains 3, 4, 5 and 6 [11].
As a prerequisite these mutagenesis studies suppose that re-
tention of the high a⁄nity binding for antagonists (or ago-
nists) is a meaningful criterion ascertaining that the overall
structure of the receptor protein is preserved, therefore per-
mitting the analysis of the agonist (or antagonist) binding. In
this manner these studies suggest that there is either limited or
no overlap in the binding sites for agonists and non-peptide
antagonists [11]. However, there are few data available con-
cerning interaction of peptide antagonists within the NK-1
receptor.
Therefore, photoa⁄nity labelling appeared to be a comple-
mentary approach to determine domains of interactions of
agonists and peptide antagonists within the NK-1 receptor.
The only antagonist used so far in photoa⁄nity studies is
an azido derivative of the non-peptide antagonist CP-96,345
[9]. It has been shown that this ligand binds the third extra-
cellular loop of the NK-1 receptor [9], while so far all peptide
agonists photoactivatable in di¡erent positions only cross-link
the second extracellular loop of the NK-1 receptor [2^4,6^8]
and the N-terminal domain [2,5].
Therefore, to try to de¢ne the interaction site between pep-
tide antagonists and the NK-1 receptor, a photoreactive ana-
logue of SP has been synthesized that contains a biotinyl
sulfone aminopentanoic acid (Bapa) at the N-terminus of
the sequence and a para-benzoyl-L-phenylalanine as the pho-
toreactive amino acid [12]. The analogue used herein is Ba-
pa0[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP. We have pre-
viously shown that this peptide has an a⁄nity for the NK-1
receptor transfected in CHO cells and antagonist activity in
both phospholipase C and adenylate cyclase second messenger
pathways [13]. Although quite low (V350 nM), this binding
a⁄nity was still adequate for photolabelling studies [13].
In this study, we have used this antagonist Bapa0[(pBzl)-
Phe8,DPro9,MePhe10,Trp(CHO)11]SP in photolabelling experi-
ments and determined its site of photoinsertion within the
human NK-1 (hNK-1) receptor expressed in CHO cells, using
the same strategy of puri¢cation via streptavidin-coated beads
and analysis by matrix-assisted laser desorption/ionization
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time of £ight (MALDI-TOF) mass spectrometry as previously
[4,7,8].
2. Materials and methods
2.1. Materials
Bapa0[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP has been synthe-
sized and characterized previously [13]. The MALDI-TOF mass spec-
trum of the peptide gave the expected m/z of the protonated molecule
(¢rst isotope): 1979.94 (with formylation on Trp11) or 1951.94 (with-
out formylation). [11-3H][Pro9]SP (60 Ci/mmol) was synthesized at
CEA (Saclay, France) according to Chassaing et al. [14]. The CHO
cell clone expressing the hNK-1 receptor (6 pmol/mg) has already
been described [15]. TPCK-treated trypsin was from Sigma, endo-
GluC from Boehringer, CNBr from Calbiochem. Streptavidin-coated
magnetic beads were obtained from Dynal.
2.2. Cell culture and membrane preparation
CHO cells expressing the hNK-1 receptor were cultured in Ham’s
F12 medium supplemented with 100 IU/ml penicillin, 100 IU/ml strep-
tomycin and 10% fetal calf serum. Cultures were kept at 37‡C in a
humidi¢ed atmosphere of 5% CO2. Stable transfection was main-
tained by geneticin (400 mg/l). Membranes were prepared as described
[15] and stored in sterile bu¡er containing 50 mM Tris^HCl pH 7.4,
1 mM EDTA, 10 mM MgCl2, 5 Wg/ml soybean trypsin inhibitor,
1 mM phenylmethylsulfonyl £uoride and 10% glycerol at 380‡C.
Proteins in membranes were quanti¢ed using the Bradford method
with bovine serum albumin as reference.
2.3. Determination of the yield of photoa⁄nity labelling
Determination of the yield of photolabelling Bapa0[(pBzl)Phe8,
DPro9,MePhe10,Trp(CHO)11]SP used at a concentration equal to its
a⁄nity (Ki = 360Q50 nM) was carried out as reported [8].
2.4. Photoa⁄nity labelling of membrane preparations
All bu¡ers used were prepared with sterile stock solutions to pre-
vent any external contamination of the samples. Membranes (1 mg
protein) were incubated for 10 min at room temperature with 500 nM
of the photoa⁄nity ligand, then irradiated on ice for 40 min at 365
nm (HPR 125-W lamp) at a distance of 6^10 cm. After irradiation, 10
WM [Pro9]SP was added for 10 min prior to centrifugation at 13 000
rpm (MSE Micro Centaur) for 2 min. The pellet was then washed
with 1 ml Tris bu¡er and centrifuged again. Photolabelled membranes
were incubated for 2 h at room temperature in 30 Wl denaturation
bu¡er consisting of 17 mM dithiothreitol, 0.1% Triton X-100, 3%
sodium dodecyl sulfate and 50 mM Tris^HCl pH 7.4.
2.5. Enzymatic and chemical cleavage before puri¢cation of the
photolabelled receptor fragments
All enzymatic digestions were performed in sterile bu¡ers. After
denaturation, photolabelled membranes were digested at room tem-
perature with 100 Wg trypsin for 15 h as described [4,7,8]. The trypsin-
digested covalent complexes were then puri¢ed with 100 Wg strepta-
vidin-coated magnetic beads and subjected or not to further digestion
with endo-GluC or to CNBr cleavage in 70% formic acid as previ-
ously described [4,7,8], the various peptide fragments being analyzed
by MALDI-TOF mass spectrometry. After endo-GluC or CNBr
cleavage, samples were again puri¢ed with the magnetic beads before
MALDI-TOF mass spectrometry analysis. CNBr cleavage was also
performed directly after denaturation of the photolabelled membranes
as described previously [4].
2.6. Identi¢cation of the labelled receptor fragments by MALDI-TOF
MS analysis
Two di¡erent sample preparations were studied. The ¢rst one cor-
responded to the elution of covalently bound peptides from the mag-
netic beads with 3 Wl of the MALDI matrix K-cyano-4-hydroxycin-
namic acid (HCCA) in 4:1 (v/v) CH3CN/H2O (0.1% tri£uoroacetic
acid) as described previously [4,7,8]. After 10 min incubation, 1 Wl
bead-free supernatant was deposited on the sample holder for MAL-
DI-TOF MS analysis. The second one was a direct deposit of 1 Wl of
matrix containing beads. In both types of deposit, spreading out the
drop by touching the metal surface with the pipette tip promoted
formation of a ‘seeding layer’ that generated a homogeneous ¢lm of
microcrystal. Generally, this second type of deposit gave more intense
and durable signal during mass spectrum acquisition. Positive ion
mass spectra (averaged over 256 laser shots) were obtained in positive
mode on a Voyager Elite (PerSeptive Biosystems) mass spectrometer
in the re£ector and delayed extraction mode. Peptides for external
calibration were deposited on the target close to the photolabelled
samples. This deposit contains a few pmol of neurotensin and the
accuracy in the mass range (800^4000 U) was estimated to be 30
ppm. Alternatively, internal calibration using the protonated molecule
of the ligand (one point calibration) was also applied that gave a
similar accuracy. For samples giving a very low ion signal (resulting
from a loss in peptide quantities due to the combined and repeated
digestions and puri¢cation steps), the ¢nal mass spectrum was ob-
tained from the average of 10^20 mass spectra (256 laser shots
each). Typically, the amount of peptide on these targets was estimated
to be in the low fmol range. Peptide receptor domains corresponding
to the mass peaks obtained were identi¢ed by using the Protein Anal-
ysis WorkSheet freeware edition (Proteomics, http://www.proteo-
mics.com) and applied to the hNK-1 receptor using the di¡erent clea-
vages.
3. Results
The synthesis (Boc strategy) and biological activity of the
photoreactive peptide antagonist Bapa0[(pBzl)Phe8,DPro9,
MePhe10,Trp(CHO)11]SP have already been described [13].
Brie£y, this analogue competes with [11-3H][Pro9]SP speci¢c
binding (Ki value was 360Q 50 nM) to the NK-1 receptor and
has antagonist activity in the adenylate cyclase and phospho-
lipase C pathways [13]. Deformylation of the C-terminal tryp-
tophan did not improve the binding potency of the peptide
analogue.
We ¢rst examined the e⁄ciency of photolabelling with this
photoreactive peptide. The yield of covalent photoa⁄nity la-
belling was determined to be 24Q 2%. Despite this apparent
low yield of photolabelling, further analysis to identify the site
of photoinsertion within the receptor was carried out.
After irradiation, the covalent complex antagonist ligand/
NK-1 receptor was digested for 15 h with trypsin at room
temperature. We observed by MALDI-TOF MS analysis of
the tryptic or combined trypsin/endo-GluC digests that Ba-
pa0[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP is cleaved by
the chymotrypsin-like activity derived from trypsin (from Sig-
ma) as previously described [4,7,8]. Protonated molecules at
Table 1







Bapa0[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP doubly oxidizeda 2011.95
aCNBr chemical treatment of the peptide, in acid conditions (HCOOH 70%) led to mono- and dioxidation of the tryptophan residue as de-
scribed [16].
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m/z 1110.54 and 982.45 (¢rst isotope) were observed. They
correspond to the N-terminal fragments 1^6 and 1^5 of this
peptide (not shown). Smaller fragments of the peptide, arising
from cleavage of Arg^Pro or Lys^Pro bonds, could not be
observed because mass spectrum acquisition was done with
a low mass gate of 800 or 1000, in order to increase the signal
to noise ratio in higher mass range. However, even with a
lower mass gate, possible interference with the matrix signals
might have hampered the reliable detection of these peptide
fragments.
In all mass spectra, we could also observe the protonated
molecule of two forms of the peptide, containing or not a
formyl on the tryptophan residue in position 11 (m/z expected
at 1979.96 and 1951.96 respectively, see Table 1). The major
peak always corresponded to the formylated form of the pep-
tide, the minor peak corresponding to the deformylated one
could arise from long-lasting or short-term incubation respec-
tively at basic (trypsin digestion) or acid pH (during mixing
with HCCA, the matrix for MALDI-TOF analysis). This par-
tial deformylation of the peptide turned out to be advanta-
geous for the mass spectrum analysis since two peaks with a
mass di¡erence of 28 u were proved to be the peptide antag-
onist signature.
After trypsin treatment, reproducible MALDI mass spectra
(over seven independent experiments) showed two protonated
molecules at m/z 2960.33Q 0.08 and 2988.30Q 0.1 (Table 2).
Blank experiments (without photolabelling) con¢rmed that
these ions are the main feature of the photolabelling. Signal
Table 2
Major feature of MALDI-MS analysis
Treatment MHþ measureda Covalent complex (receptor)^(photoligand) MHþ expected
Trypsin 2960.33Q0.08 (S169-R177)^(1^11) 2960.39
2988.30Q0.1 (S169-R177)^(1^11(CHO)) 2988.39
Trypsin+Endo-Glu C 2542.24Q0.1 (T173-R177)^(1^11) 2542.22
2570.24Q0.1 (T173-R177)^(1^11(CHO)) 2570.22
Trypsin+CNBr 2058.97Q0.05 See text 2058.94
2070.97Q0.05 See text 2070.94
CNBr 2052.95Q0.05 See text 2052.94
2070.95Q0.05 See text 2070.94
aAverage values and uncertainties were obtained from various experiments with di¡erent samples and calibrations (see text).
Fig. 1. Typical MALDI-TOF mass spectra obtained with Bapa0-
[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP and Bapa0[(pBzl)Phe8,
DPro9,MePhe10,Trp11]SP. Asterisks * and ** refer to species con-
taining the deformylated or formylated photoreactive ligand, the
square brackets indicating the receptor domain covalently linked
(see text). a: After photolabelling and combined trypsin and endo-
GluC digestions. b: Control experiment without photolabelling,
with combined trypsin and endo-GluC digestions.
Fig. 2. Typical MALDI-TOF mass spectra obtained with Bapa0-
[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP and Bapa0[(pBzl)Phe8,
DPro9,MePhe10,Trp11]SP. Asterisks * and ** refer to species con-
taining the deformylated or formylated photoreactive ligand, and
MO to monooxidized species (see text). a: After photolabelling and
combined trypsin and CNBr cleavages. b: Control experiment with-
out photolabelling, with combined trypsin digestion and CNBr
cleavage.
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at m/z 2960.33 can only correspond to the covalent attach-
ment of the entire SP analogue, Bapa0[(pBzl)Phe8,
DPro9,MePhe10,Trp11]SP, to the receptor domain S169TTET-
MPSR177 (average measured 1008.37, 1008.43 expected). The
signal at m/z 2988.30 corresponds to the covalent attachment
of the formylated form of the photoreactive analogue to the
same receptor domain (average measured 1008.37, 1008.43 u
expected) (Fig. 1a). Subsequent cleavage of the tryptic frag-
ment on magnetic beads with endo-GluC led to the identi¢-
cation in MALDI of new peptides (Fig. 1a, Table 2). Peaks at
m/z 2542.24Q 0.1 (average measured 590.28 u, 590.26 u ex-
pected) and 2570.24Q 0.1 (average measured 590.28 u,
590.26 u expected) correspond to a unique receptor fragment
T173MPSR177 linked to respectively the deformylated or for-
mylated peptide. A blank experiment without UV irradiation
only showed signals corresponding to the entire photoreactive
peptide, formylated and non-formylated forms, and the cor-
responding trypsin/chymotrypsin digestion-derived peptide
fragments (m/z 1110.55 measured, not shown) (Fig. 1b).
Subsequent cleavage of the tryptic fragment on magnetic
beads with CNBr led to the identi¢cation of two new peptides
(Fig. 2a, Table 2), at m/z 2058.97Q 0.05 and 2070.97Q 0.05.
They correspond to respectively the deformylated/monooxi-
dized and formylated peptides with an increase in mass of
91 u. This mass increment corresponds to the insertion of
^CH2SCONH2 into these photoreactive peptides. These peaks
were never observed with membranes incubated with the pho-
toreactive ligand without irradiation (Fig. 2b). Thus, the trip-
let radical of the benzophenone moiety of the antagonist pep-
tide reacted with the methyl group of the Met174 side chain in
the hNK-1 receptor, which was subsequently cleaved by
CNBr [4]. Then, the resulting ^CH2SCN modi¢ed peptides
were hydrolyzed into ^CH2SCONH2 in the acid conditions
used for CNBr cleavage or, to a lesser extent, for MALDI-
TOF analysis [4]. The same results were obtained when CNBr
cleavage was performed directly on photolabelled membranes,
after denaturation. In that case, both the hydrolyzed form
(vm=+91 corresponding to ^CH2SCONH2) and the intact
form (vm=+73 corresponding to ^CH2SCN) added to the
formylated peptide were observed at m/z 2070.95Q 0.05 and
2052.90Q 0.05 respectively (Fig. 3a). In contrast, the peak of
the deformylated monooxidized peptide expected at m/z
2059.06 was absent. Blank experiments con¢rmed that these
ions are the main feature of the photolabelling (Fig. 3b).
Chemical CNBr treatment of the ligands alone was also
studied and led to the appearance of monooxidized forms of
the deformylated and formylated peptides at m/z 1967.98Q
0.03 and 1995.98Q 0.03, respectively. In addition, the doubly
oxidized form of the formylated peptide could be detected at
m/z V2011.90 (not shown). Although this peptide antagonist
does not contain a methionine residue, mono- or dioxidation
of the peptide could still occur, probably on the tryptophan
residue as previously shown [16].
4. Discussion
Cross-linking studies with photoreactive analogues of SP
are mainly reported for peptide agonists [2^8]. All these stud-
ies have used para-benzoyl phenylalanine as the photoreactive
probe to be inserted in the peptide sequence. It has been
shown that this photoreactive amino acid in position 3 of
the sequence of SP contacts the N-terminal domain and the
second extracellular loop of the receptor [2,5], while in posi-
tions 4, 5 and 8, benzophenone only links the second extra-
cellular loop [2^4,6^8].
Besides these studies with peptide agonists, only one report
concerns photolabelling of the NK-1 receptor with an antag-
onist [9]. An azido derivative of (2S,3S)-cis-2-(diphenylmeth-
yl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo[2.2.2]octan-3-
amine or CP-96,345, a potent non-peptide antagonist, led
McDonald et al. to identify the third extracellular loop of
the NK-1 receptor as the site of photoinsertion [9].
Here we show with the use of a peptide antagonist photo-
reactive in position 8 that the site of insertion is Met174 and
more precisely the methyl group of the side chain. This methyl
of the Met174 side chain is also the site we identi¢ed for the
peptide agonist, photoactivatable at the same position [4,7].
Therefore, unlike agonists and non-peptide antagonists there
should be at least a partial overlap in the binding site of
agonists and peptide antagonists.
All the experiments in MALDI-TOF were done in the re-
£ector mode and the delayed extraction was optimized. Tak-
ing into account the low peptide signal, an average of 5^10
(or more) MALDI-TOF mass spectra (256 laser shots each)
was required to get a good signal to noise ratio and reliable
statistics on the isotope pattern. Interestingly, this e⁄cient
average procedure gives narrower peaks and likely a good
precision on m/z measurements. In addition, the external cal-
ibration was done with a deposit (same matrix+known pep-
Fig. 3. Typical MALDI-TOF mass spectra obtained with Ba-
pa0[(pBzl)Phe8,DPro9,MePhe10,Trp(CHO)11]SP and Bapa0[(pBzl)-
Phe8,DPro9,MePhe10,Trp11]SP. Asterisks * and ** refer to species
containing the deformylated or formylated photoreactive ligand, and
MO to monooxidized species (see text). a: After photolabelling and
CNBr cleavage. b: Control experiment without photolabelling, with
CNBr cleavage.
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tide) close to the sample studied (1^2 mm). All these exper-
imental conditions converge towards a precision of m/z mea-
surement typically better than the 50 ppm expected from the
quali¢cation record of our apparatus (30 ppm).
Photolabelling was done with 1 mg of membrane proteins
containing about 5000 fmol of hNK-1 receptor. We used a
concentration of photolabelled antagonist that is close to its
binding a⁄nity, meaning that no more than 50% of receptors
can be bound. The yield of photolabelling was about 20% for
that analogue. Thus 500 fmol of receptors could be covalently
bound. We estimated that about 50% of this covalent complex
is then lost during enzymatic digestion because the antagonist
peptide can be cleaved between biotin, used for puri¢cation,
and the photoreactive amino acid; 250 fmol of covalent com-
plex remained. We previously measured that the yield of pu-
ri¢cation using streptavidin-coated magnetic beads is about
80^90% [17], leading to 200 fmol of puri¢ed complex. One-
third is then deposited on the target for MALDI analysis, i.e.
about 60 fmol. Finally, the sample is never exhausted by the
laser shots. Moreover, this estimation of fmol amount is in
good agreement with the ion signal intensity studied with
known quantities of the photoreactive ligand alone, in similar
MALDI conditions. For all these experimental reasons we
estimated that the quantity of covalent complex being ana-
lyzed is in the low fmol range.
Insertion of benzophenone-containing SP analogues on the
side chain of methionine is now frequently observed [3,4,8]. In
fact, it was recently suggested that methionine is the amino
acid preferred by benzophenone [18].
Benzophenone is widely used in photolabelling of non-pu-
ri¢ed proteins because it produces highly e⁄cient covalent
modi¢cations of macromolecules with remarkable site speci-
¢city [19], as exempli¢ed herein where non-speci¢c photola-
belling was not observed. This particular reactivity of benzo-
phenone for methionine is now elegantly used as a general
methodology to analyze the site of photoinsertion of peptide
analogues within their speci¢c receptor [20,21]. Described as
the methionine proximity assay, this method uses p,pP-nitro-
benzoylphenylalanine (NO2Bpa), which displays more selec-
tivity than benzophenone for Met residues. Therefore a pho-
toreactive analogue ‘‘containing such modi¢ed benzophenone
moieties does not label a receptor protein unless a Met residue
is in the immediate vicinity’’ [20,21]. It should be kept in mind
that at the atom level, the photoinsertion does not always
occur on the methyl but also on the CQH2 of the methionine
side chain and in that case, CNBr cleavage is atypical as we
recently demonstrated [8,22]. Insertion of the photoprobe
on CH3 gives a mass increase of 73 (^CH2SCN) or 91
(^CH2SCONH2) after CNBr cleavage. However, photoinser-
tion in CQH2 leads to a loss in mass of 48 or 64 corresponding
to the formation after CNBr treatment of the ethylenic and
epoxide or ketone derivatives of the photoprobe as described
[8,22].
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